Dikloron

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dikloron

Property Description
Active Ingredient Diclofenac Sodium
Form Varies (e.g., tablet, injectable, topical gel)
Pharmacological Class Nonsteroidal Anti-Inflammatory Drug (NSAID)
General Purpose Relief from pain, inflammation, and fever
Origin Synthetic (Phenylacetic acid derivative)

Dikloron is a preparation whose active ingredient is Diclofenac Sodium, which places it in the major pharmaceutical category of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). It is a synthetic therapeutic agent, structurally derived from phenylacetic acid, and is fundamentally used to address symptoms associated with inflammatory states, including pain, swelling, and fever.


What is Dikloron and Its Active Substance?

The medicine Dikloron contains the powerful active ingredient Diclofenac Sodium, classifying it as a Nonsteroidal Anti-Inflammatory Drug (NSAID). Its status as an NSAID is associated with effectiveness against inflammatory pain across various therapeutic areas. This compound, an organic structure related to phenylacetic acid, is a synthetic agent. The key takeaway for the patient is that this classification means the medicine is specifically designed to target both the sensation of pain and the underlying biological process of swelling, a crucial differentiation from simple analgesics.


Pharmacological Class and Primary Therapeutic Actions

The pharmacological class of Diclofenac is defined by its core functional actions: providing relief through analgesia (pain relief), possessing a significant anti-inflammatory effect, and the ability to reduce fever (antipyresis). Its primary benefit involves the targeted inhibition of Cyclooxygenase (COX) enzymes, which are responsible for creating the prostaglandins that mediate pain and inflammation. This therapeutic profile is utilized for common inflammatory issues, such as relieving discomfort in conditions involving joint or muscle inflammation.


Available Preparations and Single-Ingredient Nature

Dikloron is typically a single-ingredient product (monotherapy), driven solely by the Diclofenac Sodium component. A differentiating factor of Diclofenac is its diverse manufacturing in various physical dosage forms to allow for an appropriate administration route, including oral preparations (such as tablets or capsules), injections for parenteral use, suppositories for rectal use, and localized applications like gels. This wide spectrum of available forms ensures the medicine's core therapeutic effect can be delivered for localized symptoms or acute systemic inflammatory conditions.

Regulatory References

  1. Diclofenac - StatPearls - NCBI Bookshelf
  2. WHO Model Lists of Essential Medicines

What side effects are possible with Dikloron?

Possible Side Effects and Safety Information

Dikloron, containing the active substance Diclofenac Sodium, is classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID). Its official safety profile is categorized by the potential for adverse reactions affecting various physiological systems and is documented according to frequency standards from regulatory bodies.

Frequency-Classified Adverse Reactions

The most frequently reported effects, classified as Common in regulatory documents, typically involve the gastrointestinal system, such as nausea, vomiting, indigestion, and abdominal pain, along with effects on the nervous system like headache and dizziness. Adverse events classified as Rare include gastrointestinal bleeding, ulceration, and various hypersensitivity reactions. Very Rare documented effects include severe dermatological reactions, such as Stevens-Johnson syndrome, and acute renal failure.

Serious Safety Considerations

The official labeling highlights the potential for Serious Cardiovascular Thrombotic Events, including myocardial infarction (heart attack) and stroke. The risk for these serious events, as well as Serious Gastrointestinal Adverse Events (bleeding and perforation), is documented as potentially increasing with higher doses and longer duration of use. Older adults are noted in regulatory documents as a population with a greater risk for serious adverse gastrointestinal and cardiovascular outcomes.

Official restrictions listed in the product information include contraindications for individuals with active gastrointestinal ulceration or bleeding and non-use in the setting of coronary artery bypass graft (CABG) surgery.

Overdose and Emergency Response

Overdose and When to Seek Help: Regulatory Guidance

Official regulatory documentation defines the Dikloron (Diclofenac Sodium) overdose profile based on specific physiological manifestations and mandated emergency actions. All suspected or confirmed overdose scenarios require an immediate response.

Overdose Manifestations Severe Outcomes Immediate Action Mandate
Gastrointestinal distress (vomiting, stomach pain, bleeding) Acute Renal Failure Seek Immediate Medical Attention
CNS effects (headache, dizziness, drowsiness, tinnitus) Hepatic Damage, Seizures, Coma Contact Emergency Services

Overdose with a large amount of the drug may lead to these effects, particularly those involving the Gastrointestinal, Central Nervous, Renal, and Hepatic systems. Overdose severity may be exacerbated in patients with pre-existing renal or hepatic impairment.

Management is strictly symptomatic and supportive as official labeling states no specific antidote is known. Procedures may include the administration of Activated Charcoal or Gastric Lavage if ingestion was recent. Due to the risk of severe outcomes, hospital monitoring is often required to stabilize the patient and manage complications.

Therapeutic Uses of Dikloron

Main Uses and Benefits of Dikloron (Diclofenac Sodium)

The active ingredient in Dikloron (Diclofenac Sodium) is used to help with a variety of inflammatory conditions and is relevant for easing symptoms across several key domains. This medication is applied where additional symptomatic support is needed, primarily for conditions presenting with systemic or localized discomfort.

The medication is utilized to help with the reduction of fever and for easing symptoms that create noticeable physiological strain.

The medicine is relevant for easing symptoms associated with conditions like Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis, and may assist with acute episodes such as gouty arthritis, migraine headaches, and primary dysmenorrhea. It is also relevant in clinical settings marked by increased discomfort or tension and may be part of symptomatic management for sudden onset issues like postoperative pain or acute traumatic injuries. Dikloron provides supportive relief that helps ease the overall symptom load, assists with managing joint comfort, and contributes to easing the symptoms that interfere with functional stability during periods of heightened symptoms.


Quick Fact: Relief for Inflammatory Symptoms (The medication is relevant for easing symptoms related to inflammatory or irritative states, often used during phases when symptoms become more noticeable.)

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Dikloron — Official Regulatory Information

Contraindicated Populations (Must NOT use):

  • Patients with known hypersensitivity to diclofenac, aspirin, or any other NSAID.
  • Individuals with active gastrointestinal ulceration, bleeding, or perforation.
  • Patients with severe heart failure (NYHA class II–IV) or established ischemic heart disease, peripheral arterial disease, or cerebrovascular disease.
  • Patients immediately following coronary artery bypass graft (CABG) surgery.

Age and Physiological States:

  • Pregnancy: Contraindicated in the third trimester (starting at 30 weeks gestation) and generally avoided from 20 weeks onward due to risks to the fetus.
  • Lactation: Use is not recommended as the substance passes into breast milk.
  • Pediatrics: Systemic use is not established or approved for children under age 12 or 16, depending on the specific formulation and regulatory label.

Condition-Specific Restrictions:

  • Use is contraindicated in patients with severe renal impairment or severe hepatic impairment.
  • Patients with risk factors for cardiovascular events (e.g., hypertension, diabetes, smoking) should be prescribed this medicine only after careful regulatory consideration.

What should I know about interactions with other medicines?

Dikloron Interactions with other medicines and products

Official regulatory information for Diclofenac Sodium (Dikloron) establishes several interaction constraints and documented effects with co-administered substances.

Interaction Classification Relevant Combinations or Substances
Formally Restricted/Contraindicated Other NSAIDs (including COX-2 inhibitors) and Aspirin (analgesic doses) are generally prohibited due to the potential for additive GI and systemic effects. Use is also contraindicated in the setting of CABG surgery (Coronary Artery Bypass Graft).
Increased Exposure Risk Co-administration with the inhibitor Voriconazole is documented to significantly increase Diclofenac plasma concentration (AUC increase of 78%) through inhibition of its CYP2C9-mediated metabolism. Diclofenac may also increase serum levels of Lithium and Digoxin and raise the risk of Methotrexate toxicity by reducing their renal clearance.
Additive Pharmacodynamic Risk Combining Dikloron with Anticoagulants (e.g., Warfarin), Antiplatelet Agents, or SSRIs/SNRIs carries a documented risk of serious bleeding events due to additive effects. Furthermore, it may reduce the effectiveness of Diuretics and ACE Inhibitors/ARBs, particularly increasing the risk of renal function deterioration in high-risk groups, such as elderly patients.
Other Constraints Oral forms are sometimes advised to be taken with or after food. Chronic alcohol consumption is noted to increase the risk of GI bleeding.

This structure reflects the regulatory emphasis on preventing additive system risks (e.g., GI, renal) and managing the altered exposure of both Diclofenac and several critical co-administered medicines.

Mechanism of Action

Enzyme Inhibition of Prostaglandin Synthesis

The core function of Diclofenac is to act as a reversible inhibitor of the Cyclooxygenase (COX) enzymes (COX-1 and COX-2). By blocking these enzymes, the drug suppresses the crucial early step in the Arachidonic Acid Cascade, thereby reducing the production of potent chemical mediators like prostaglandins ( PGE2 and PGI2). This modulation initiates a downstream physiological cascade that restricts the concentration of pro-inflammatory mediators.


Modulation of Nociceptor and Thermoregulatory Signaling

The molecular effect of reduced prostaglandins translates directly into two systemic physiological changes: the modulation of nociceptor excitability and the alteration of the hypothalamic thermoregulatory set-point. In the periphery, lower PGE2 levels decrease the sensitivity of nerve endings, attenuating the electrical signaling cascade of nociceptors. In the central nervous system, this suppression allows the hypothalamus to reduce the body's core temperature set-point, resulting in a change in heat dissipation dynamics.


Physiological Scope and Constraints

The mechanism exerts a specific modulation of signaling pathways, resulting in changes to vascular dynamics (permeability) and sensory nerve excitability. However, the mechanism's influence is restricted to modulating immediate physiological responses, and it does not alter the underlying structural or immunological processes of chronic pathological states. The mechanism exhibits limitations in physiological contexts dominated by non-prostaglandin signaling cascades, such as those initiated by mechanical tissue deformation.

Dosage and Administration Information

The use of Dikloron, which contains the active substance Diclofenac Sodium, is based on established administration and dosing guidelines. This medicine is available for use via multiple administration routes, including oral preparations (such as tablets and solutions), topical applications (gels), and parenteral forms (intramuscular or intravenous solutions).


Dosing and Frequency Patterns

For systemic use in chronic conditions, the typical maintenance dosage range is 100 mg to 200 mg per day of the active substance, which is administered in divided doses throughout the day. Conversely, treatment for acute, self-limiting issues may utilize a single, fixed dose, such as the 50 mg oral powder for acute migraine episodes. The administration protocol typically emphasizes using the lowest effective dosage for the **shortest duration possible.


Required Administration Procedures

Proper use is contingent upon adherence to specific procedural rules tied to the dosage form. Immediate-release oral capsules are to be taken on an empty stomach to ensure appropriate absorption. For the oral powder form, the contents must be thoroughly mixed only with a small amount of plain water (1 to 2 ounces) and must be consumed without delay. Furthermore, certain oral preparations, such as delayed-release tablets, must not be crushed, broken, or chewed, as this alters the intended mechanism of drug release. For the parenteral route, intramuscular administration is generally restricted to no more than two days of use.

Recent Clinical Evidence

Evidence for Use in Chronic Joint Conditions

The research foundation for Dikloron's active ingredient in chronic conditions, such as Osteoarthritis (OA), Rheumatoid Arthritis (RA), and Ankylosing Spondylitis (AS), has been built mainly through Randomized Controlled Trials (RCTs) and systematic reviews. These studies have been used in research exploring how symptoms change over time. Researchers have focused on outcomes related to physical discomfort and daily functioning or activity level, using tools like the WOMAC index to measure changes in these assessed parameters. Findings describe patterns observed regarding patient-reported outcomes describing perceived discomfort and outcomes reflecting daily functioning or activity level over defined time intervals.


Research on Acute Pain States

Research for situations involving sudden or short-term discomfort—including acute migraine attacks, primary dysmenorrhea, and postoperative pain—has primarily relied on short-term, placebo-controlled RCTs. These trials were applied in research contexts involving fluctuating or unstable symptoms for conditions associated with acute or disruptive episodes. The studies monitored outcomes describing episodic or acute changes, specifically focusing on the measurement of time to the onset of relief and the patient's need for rescue pain medication. This evidence is relevant in trials assessing short-term or episodic symptom patterns.


Long-Term Data and Follow-Up Duration

Studies involve various follow-up durations. For chronic joint conditions, some long-term extension studies tracked outcomes for periods up to a year. However, there is limited information for long-term outcomes regarding the durability of symptom change beyond these controlled trial settings. Long-term effects are not fully established in terms of continuous relief for all studied populations, and findings describe group patterns, not personal outcomes.


Research Gaps and Uncertainty

Despite the research base, certainty remains low in several key areas. The follow-up durations were limited in many primary efficacy trials, leaving long-term effects not fully established for certain treatment approaches. Furthermore, data for certain groups remain insufficient. For instance, data are still emerging for pediatric populations, and research was not studied for use in patients who are pregnant or breastfeeding. The overall evidence highlights what is known—and what is still uncertain—about the medicine's research profile.

Key Studies & References Diclofenac topical solution compared with oral diclofenac: a pooled safety analysis (Evidence on topical vs. oral use)

Frequently Asked Questions (FAQ)

Common questions about Dikloron (FAQ)

Q: How long does it usually take for Dikloron to start working?

A: Clinical information indicates that studies monitor the time until the onset of pain relief is achieved. According to official product information, taking certain oral forms with food may slow absorption, which could potentially delay the start of the medicine's action.

Q: Does Dikloron interact with blood thinners?

A: Yes, regulatory information indicates that co-administration with anticoagulant medicines, such as Warfarin, or antiplatelet agents has a documented potential to increase the risk of serious bleeding events.

Q: What happens if I combine Dikloron with alcohol?

A: Chronic alcohol consumption is noted in official warnings as a factor that can increase the risk of serious gastrointestinal bleeding while using this medicine. Patients should be aware of this potential additive risk.

Q: What's the difference between Dikloron tablets and suppositories?

A: Dikloron is manufactured in multiple forms, including oral tablets and suppositories. The difference lies in the route of administration, which allows the active substance to be delivered by the route that is most appropriate for a patient's condition.

Q: Why is Dikloron sometimes prescribed for gout attacks?

A: The medicine is officially indicated for the management of signs and symptoms related to acute painful conditions. Its strong anti-inflammatory properties mean it may be used to manage the inflammation experienced in acute arthritic flares.

Q: Does Dikloron interact with antidepressant medications?

A: Yes, official regulatory documents note an interaction risk. Combining this medicine with certain antidepressants—specifically SSRIs or SNRIs—has a documented potential to increase the risk of serious bleeding events.

Q: Is it safe to use topical Dikloron (gel) with the oral tablets?

A: Regulatory documents caution that combining topical and oral NSAIDs may increase the risk of cumulative systemic side effects. This includes effects such as those potentially affecting the gastrointestinal system.

Q: Do people use Dikloron for back pain relief?

A: The official indications for this medicine include the management of both acute and chronic painful conditions. The general scope includes the management of musculoskeletal pain, such as back pain, based on its effectiveness against pain and inflammation.

Q: Can Dikloron help with menstrual cramps?

A: Yes, regulatory documents formally indicate this medicine for the relief of pain associated with primary dysmenorrhea, which is the medical term for menstrual cramps.

Q: How many hours does the effect of Dikloron typically last?

A: The terminal half-life of the active substance is approximately 2 hours. Maintaining a therapeutic effect may require taking the medicine in divided doses throughout the day, as directed by a healthcare professional.

Q: Is it normal to feel a stomach upset after taking Dikloron?

A: Gastrointestinal effects like nausea, vomiting, indigestion, and abdominal pain are officially classified as common adverse effects. These effects are among the most frequently reported in safety documents.

Q: Does Dikloron make you drowsy or tired?

A: Yes, official safety information documents potential effects on the nervous system. Adverse reactions listed include dizziness, somnolence (sleepiness), and headache.

Q: Is there a risk of allergic reaction with Dikloron?

A: Yes, as with all medicines, allergic reactions have been reported. Regulatory documents state that serious reactions, including anaphylaxis, can occur even without a person having prior exposure to the medicine.

Q: Is Dikloron safe for older people?

A: Official safety information notes that older adults have a greater risk for serious cardiovascular and gastrointestinal side effects. The use protocol therefore emphasizes minimizing the dose and duration to manage this risk.

Q: Why do some people say they have to take Dikloron with food?

A: The required procedure depends on the specific formulation. While some forms are advised to be taken with or after food to help with gastrointestinal tolerance, other forms, such as immediate-release capsules, must be taken on an empty stomach to ensure proper absorption.

Q: Is Dikloron available over the counter in some countries?

A: The legal status of the medicine varies depending on the country and the specific formulation. In some regions, lower-strength topical forms are available without a prescription, while stronger and systemic forms generally require one.

Q: What do researchers say about the long-term safety of Dikloron?

A: Official warnings state that long-term use, especially at high doses, is associated with an increased risk of serious cardiovascular thrombotic events (like heart attack or stroke) and serious gastrointestinal adverse events.

Q: Is it normal to notice a change in urine color while on Dikloron?

A: The official label does not list a simple change in urine color as a common side effect. However, very rare urinary tract adverse effects, such as hematuria (blood in the urine), have been reported in safety documents.

Q: Does Dikloron affect sleep?

A: The list of reported nervous system adverse reactions includes both somnolence (drowsiness) and insomnia (difficulty falling or staying asleep). The medicine may affect sleep patterns in some people.

Q: Does Dikloron have a risk of causing addiction?

A: No, the medicine is classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID). It is not categorized as a controlled substance or narcotic and does not carry a risk of causing addiction.

Q: Is there a maximum time limit for using Dikloron continuously?

A: Regulatory mandates emphasize using the lowest effective dosage for the shortest duration possible to minimize risks. For example, the use of the injectable form is generally restricted to no more than two consecutive days.

Q: Can Dikloron cause sensitivity to sunlight?

A: Yes, official safety data reports photosensitivity, which is an increased sensitivity to sunlight, as a possible adverse reaction. Patients who experience this may be advised to limit their exposure to the sun.

Q: What are the signs of taking too much Dikloron?

A: The official overdosage section of the product information states that symptoms may include lethargy, drowsiness, nausea, vomiting, and gastrointestinal bleeding. Less commonly, severe effects such as kidney failure have been reported.

Q: Why is Dikloron mentioned in relation to dental pain?

A: The medicine is indicated for the management of acute painful conditions. This broad indication often covers severe inflammatory pain, such as the kind experienced after certain dental procedures or surgery.

Q: Does Dikloron affect fertility in men or women?

A: Regulatory documents state that, like other NSAIDs, this medicine may cause a reversible delay in ovulation. Its use is therefore not recommended for women who are actively trying to conceive.

Q: Can I drive or operate machinery after taking Dikloron?

A: Official safety information states that patients who experience adverse effects such as dizziness, sleepiness, or visual disturbances should avoid driving or operating machinery.

Q: Are there any dietary restrictions while using Dikloron?

A: There are no widespread dietary restrictions other than the documented caution regarding chronic alcohol consumption. However, some oral forms must be taken with food to improve gastrointestinal tolerance.

Q: Why might Dikloron be given as an injection?

A: The injectable form is typically reserved for acute, severe pain conditions where a rapid onset of relief is needed. Examples include managing moderate to severe post-operative pain or treating an acute migraine attack.

Q: What's the evidence supporting Dikloron use for sports injuries?

A: The medicine is broadly indicated for acute painful and inflammatory conditions. This covers the symptoms—pain, swelling, and inflammation—that typically arise from musculoskeletal issues like common sports injuries.

Q: Can Dikloron be used during the recovery phase after surgery?

A: The injectable form is indicated for moderate to severe post-operative pain management. However, it is strictly contraindicated immediately following Coronary Artery Bypass Graft (CABG) surgery.

How should Dikloron be stored and disposed of?

Official Storage and Disposal Instructions

Regulatory documents mandate specific conditions for storing and disposing of Dikloron (diclofenac sodium) to maintain its stability and ensure safety.

Storage Requirements:

  • Temperature: Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). Do not freeze or expose to excessive heat.
  • Protection: Keep the medication in its original, tightly closed container, protected from both light and moisture.
  • Safety: The product must be stored out of the reach of children and pets.

Disposal Requirements:

  • Expired/Unused Medicine: Do not keep outdated or unused medication. Consult a healthcare professional or utilize an official drug take-back program for disposal.
  • Environmental Protection: Disposal must avoid release into the environment, including sewers or surface water, in accordance with local regulatory requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dikloron found in:

A-Z Index: